ABIVAX Société Anonyme (AAVXF)
| Previous close | 25.60 |
| Open | 25.60 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 25.60 - 25.60 |
| 52-week range | 22.75 - 39.70 |
| Volume | |
| Avg. volume | 11 |
| Market cap | 428.319M |
| Beta (5Y monthly) | 1.39 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.62 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- EQS Group
ABIVAX: Abivax announces annual ordinary and extraordinary general meeting on June 9, 2022, and the availability of the preparatory documents
DGAP-News: ABIVAX / Key word(s): AGM/EGMABIVAX: Abivax announces annual ordinary and extraordinary general meeting on June 9, 2022, and the availability of the preparatory documents 18.05.2022 / 18:00 The issuer is solely responsible for the content of this announcement.Abivax announces annual ordinary and extraordinary general meeting on June 9, 2022, and the availability of the preparatory documentsPARIS, France, May 18, 2022 – 06:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX
- EQS Group
Abivax publishes Universal Registration Document 2022 'Document d'Enregistrement Universel'
DGAP-News: ABIVAX / Key word(s): Annual ReportAbivax publishes Universal Registration Document 2022 'Document d'Enregistrement Universel' 28.04.2022 / 18:00 The issuer is solely responsible for the content of this announcement.Abivax publishes Universal Registration Document 2022 "Document d'Enregistrement Universel"PARIS, France, April 28, 2022 - 6:00 p.m. (CEST) - Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company developing novel therapies that modulate th
- EQS Group
Abivax reports excellent one-year efficacy and safety data of ABX464 phase 2b maintenance trial in ulcerative colitis
DGAP-News: ABIVAX / Key word(s): Study results06.04.2022 / 18:00 The issuer is solely responsible for the content of this announcement.Abivax reports excellent one-year efficacy and safety data of ABX464 phase 2b maintenance trial in ulcerative colitis Interim analysis demonstrates best-in-class clinical remission in 55.3% of 217 ulcerative colitis (UC) patients (full analysis set) after 48 weeks of once-daily oral 50mg ABX464 Moreover, in the subgroup of patients who had at least a clinical res
